Assessment of a Cellular Host Response Test as a Sepsis Diagnostic for Those With Suspected Infection in the Emergency Department

Supplemental Digital Content is available in the text. Objectives: Sepsis is a common cause of morbidity and mortality. A reliable, rapid, and early indicator can help improve efficiency of care and outcomes. To assess the IntelliSep test, a novel in vitro diagnostic that quantifies the state of immune activation by measuring the biophysical properties of leukocytes, as a rapid diagnostic for sepsis and a measure of severity of illness, as defined by Sequential Organ Failure Assessment and Acute Physiology and Chronic Health Evaluation-II scores and the need for hospitalization. Design, Setting, SUBJECTS: Adult patients presenting to two emergency departments in Baton Rouge, LA, with signs of infection (two of four systemic inflammatory response syndrome criteria, with at least one being aberration of temperature or WBC count) or suspicion of infection (a clinician order for culture of a body fluid), were prospectively enrolled. Sepsis status, per Sepsis-3 criteria, was determined through a 3-tiered retrospective and blinded adjudication process consisting of objective review, site-level clinician review, and final determination by independent physician adjudicators. MEASUREMENTS AND MAIN RESULTS: Of 266 patients in the final analysis, those with sepsis had higher IntelliSep Index (median = 6.9; interquartile range, 6.1–7.6) than those adjudicated as not septic (median = 4.7; interquartile range, 3.7–5.9; p < 0.001), with an area under the receiver operating characteristic curve of 0.89 and 0.83 when compared with unanimous and forced adjudication standards, respectively. Patients with higher IntelliSep Index had higher Sequential Organ Failure Assessment (3 [interquartile range, 1–5] vs 1 [interquartile range, 0–2]; p < 0.001) and Acute Physiology and Chronic Health Evaluation-II (7 [interquartile range, 3.5–11.5] vs 5 [interquartile range, 2–9]; p < 0.05) and were more likely to be admitted to the hospital (83.6% vs 48.3%; p < 0.001) compared with those with lower IntelliSep Index. CONCLUSIONS: In patients presenting to the emergency department with signs or suspicion of infection, the IntelliSep Index is a promising tool for the rapid diagnosis and risk stratification for sepsis.

[1]  Jongyoon Han,et al.  Label-Free Biophysical Markers from Whole Blood Microfluidic Immune Profiling Reveal Severe Immune Response Signatures. , 2021, Small.

[2]  Terrell S. Caffery,et al.  Development and validation of a cellular host response test as an early diagnostic for sepsis , 2021, bioRxiv.

[3]  D. Winslow,et al.  Impact of Sepsis Mandates on Sepsis Care: Unintended Consequences. , 2020, The Journal of infectious diseases.

[4]  E. Septimus.  Sepsis Perspective 2020. , 2020, The Journal of infectious diseases.

[5]  S. W. Long,et al.  Role of Rapid Diagnostics in Diagnosis and Management of Patients With Sepsis. , 2020, The Journal of infectious diseases.

[6]  Sameer S. Kadri,et al.  Infectious Diseases Society of America Position Paper: Recommended Revisions to the National Severe Sepsis and Septic Shock Early Management Bundle (SEP-1) Sepsis Quality Measure. , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  C. Rhee,et al.  Sepsis trends: increasing incidence and decreasing mortality, or changing denominator? , 2020, Journal of thoracic disease.

[8]  Seungok Lee,et al.  Procalcitonin as a prognostic marker for sepsis based on SEPSIS‐3 , 2019, Journal of clinical laboratory analysis.

[9]  T. Rimmele,et al.  Immune Profiling Panel: A Proof-of-Concept Study of a New Multiplex Molecular Tool to Assess the Immune Status of Critically Ill Patients , 2019, bioRxiv.

[10]  M. Levy,et al.  Physician agreement on the diagnosis of sepsis in the intensive care unit: estimation of concordance and analysis of underlying factors in a multicenter cohort , 2019, Journal of Intensive Care.

[11]  Yong Won Kim,et al.  Procalcitonin as a diagnostic marker for sepsis/septic shock in the emergency department; a study based on Sepsis‐3 definition , 2019, The American journal of emergency medicine.

[12]  E. Crouser,et al.  Epidemiology and Costs of Sepsis in the United States—An Analysis Based on Timing of Diagnosis and Severity Level* , 2018, Critical care medicine.

[13]  Russell R. Miller,et al.  Validation of a Host Response Assay, SeptiCyte LAB, for Discriminating Sepsis from Systemic Inflammatory Response Syndrome in the ICU , 2018, American journal of respiratory and critical care medicine.

[14]  Terrell S. Caffery,et al.  Rapid Biophysical Analysis of Host Immune Cell Variations Associated with Sepsis , 2018, American journal of respiratory and critical care medicine.

[15]  H. Masur,et al.  Infectious Diseases Society of America (IDSA) POSITION STATEMENT: Why IDSA Did Not Endorse the Surviving Sepsis Campaign Guidelines , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[16]  C. Natanson,et al.  Evidence Underpinning the Centers for Medicare & Medicaid Services' Severe Sepsis and Septic Shock Management Bundle (SEP-1) , 2018, Annals of Internal Medicine.

[17]  C. Natanson,et al.  Evidence Underpinning the U.S. Government–Mandated Hemodynamic Interventions for Sepsis: A Systematic Review , 2018 .

[18]  Susan Gruber,et al.  Incidence and Trends of Sepsis in US Hospitals Using Clinical vs Claims Data, 2009-2014 , 2017, JAMA.

[19]  C. Seymour,et al.  Improved Early Detection of Sepsis in the ED With a Novel Monocyte Distribution Width Biomarker , 2017, Chest.

[20]  A. Pernestig,et al.  Diagnostic accuracy of procalcitonin, neutrophil-lymphocyte count ratio, C-reactive protein, and lactate in patients with suspected bacterial sepsis , 2017, PloS one.

[21]  Junfeng Sun,et al.  Early Goal-Directed Therapy for Sepsis: A Novel Solution for Discordant Survival Outcomes in Clinical Trials , 2017, Critical care medicine.

[22]  Sangeeta Mehta,et al.  Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock: 2016 , 2017, Intensive Care Medicine.

[23]  H. Pavenstädt,et al.  Sepsis recognition in the emergency department – impact on quality of care and outcome? , 2016, BMC Emergency Medicine.

[24]  Anthony F Massaro,et al.  Diagnosing sepsis is subjective and highly variable: a survey of intensivists using case vignettes , 2016, Critical Care.

[25]  Stephen L. Jones,et al.  Outcomes and Resource Use of Sepsis-associated Stays by Presence on Admission, Severity, and Hospital Type , 2016, Medical care.

[26]  R. Bellomo,et al.  The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). , 2016, JAMA.

[27]  Henry E. Wang,et al.  Community-, Healthcare-, and Hospital-Acquired Severe Sepsis Hospitalizations in the University HealthSystem Consortium , 2015, Critical care medicine.

[28]  F. Kokturk,et al.  Platelet and mean platelet volume kinetics in adult patients with sepsis , 2015, Platelets.

[29]  M. Levy,et al.  Empiric Antibiotic Treatment Reduces Mortality in Severe Sepsis and Septic Shock From the First Hour: Results From a Guideline-Based Performance Improvement Program* , 2014, Critical care medicine.

[30]  N. Nesseler,et al.  The liver in sepsis , 2012 .

[31]  Dino Di Carlo,et al.  Hydrodynamic stretching of single cells for large population mechanical phenotyping , 2012, Proceedings of the National Academy of Sciences.

[32]  J. Kline,et al.  The Sequential Organ Failure Assessment score for predicting outcome in patients with severe sepsis and evidence of hypoperfusion at the time of emergency department presentation* , 2009, Critical care medicine.

[33]  P. Harris,et al.  Research electronic data capture (REDCap) - A metadata-driven methodology and workflow process for providing translational research informatics support , 2009, J. Biomed. Informatics.

[34]  S. Waikar,et al.  Creatinine kinetics and the definition of acute kidney injury. , 2009, Journal of the American Society of Nephrology : JASN.

[35]  K. Wood,et al.  Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock* , 2006, Critical care medicine.

[36]  M. Levy,et al.  2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference , 2003, Intensive care medicine.

[37]  Mitchell M. Levy,et al.  2001 SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference , 2003, Intensive Care Medicine.

[38]  J. E. Carceller.  American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis , 1992, Critical care medicine.